FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199672484> ?p ?o ?g. }

• W3199672484 endingPage "56" @default.
• W3199672484 startingPage "50" @default.
• W3199672484 abstract "to report toxicity and cosmetic outcome with a median follow-up of 6 years of a phase II trial of hypofractionated radiotherapy with volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) for early-stage breast cancer after conservative surgery.From August 2010 to September 2014, patients requiring adjuvant radiotherapy for early-stage breast cancer were treated according to a phase I-II protocol with SIB to 40.5 and 48 Gy to the breast and the boost region, respectively, with VMAT technique. The primary endpoint evaluated the treatment feasibility regarding adherence to required dose constraints for target, heart and lungs. Acute and late toxicity, local and distant control were secondary endpoints.450 patients were included in the trial and analysed after a median follow-up of 6 years. Acute toxicity was already presented in a previous paper. Regarding late toxicity, 93% of patients had no skin alteration at five years, while 5.3% and 1.3% did record G1 and G2 residual toxicity, respectively. Cosmetic outcome was scored good or excellent in almost all cases (97.2%), fair only in 2.3% of patients. Residual tenderness in the irradiated breast was reported by 10% of patients. Cosmesis and breast pain improved during follow-up. Two cases of G2 pneumonitis and two cases of ischemic cardiopathy were registered during follow-up. Five cases presented local recurrence in the homolateral breast, four patients had a new primary cancer in the contralateral breast, while distant metastasis developed in 7 patients.After more than six years, hypofractionated VMAT with SIB for adjuvant radiotherapy in early-stage breast cancer patients remains a safe and effective approach. Mature data on skin toxicity and cosmetic outcome are encouraging. However, longer follow-up is required to evaluate local control, cardiac toxicity and secondary carcinogenesis." @default.
• W3199672484 created "2021-09-27" @default.
• W3199672484 creator A5001738256 @default.
• W3199672484 creator A5002993236 @default.
• W3199672484 creator A5004940783 @default.
• W3199672484 creator A5016966644 @default.
• W3199672484 creator A5029600028 @default.
• W3199672484 creator A5044032137 @default.
• W3199672484 creator A5046440167 @default.
• W3199672484 creator A5059081660 @default.
• W3199672484 creator A5061765305 @default.
• W3199672484 creator A5063598635 @default.
• W3199672484 creator A5071706202 @default.
• W3199672484 creator A5075534279 @default.
• W3199672484 creator A5087468389 @default.
• W3199672484 date "2021-11-01" @default.
• W3199672484 modified "2023-10-16" @default.
• W3199672484 title "Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost" @default.
• W3199672484 cites W1963580523 @default.
• W3199672484 cites W1983091326 @default.
• W3199672484 cites W2030273299 @default.
• W3199672484 cites W2036871048 @default.
• W3199672484 cites W2075638923 @default.
• W3199672484 cites W2096499183 @default.
• W3199672484 cites W2101429637 @default.
• W3199672484 cites W2103608035 @default.
• W3199672484 cites W2143561393 @default.
• W3199672484 cites W2154375587 @default.
• W3199672484 cites W2168124422 @default.
• W3199672484 cites W2171516582 @default.
• W3199672484 cites W2519293369 @default.
• W3199672484 cites W2519353639 @default.
• W3199672484 cites W2742976566 @default.
• W3199672484 cites W2767113177 @default.
• W3199672484 cites W2800319280 @default.
• W3199672484 cites W2892569165 @default.
• W3199672484 cites W2993667428 @default.
• W3199672484 cites W3021410191 @default.
• W3199672484 cites W3022548009 @default.
• W3199672484 cites W3036271213 @default.
• W3199672484 cites W3081515379 @default.
• W3199672484 cites W3111165585 @default.
• W3199672484 cites W3119005666 @default.
• W3199672484 cites W993406450 @default.
• W3199672484 doi "https://doi.org/10.1016/j.radonc.2021.09.006" @default.
• W3199672484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34537289" @default.
• W3199672484 hasPublicationYear "2021" @default.
• W3199672484 type Work @default.
• W3199672484 sameAs 3199672484 @default.
• W3199672484 citedByCount "10" @default.
• W3199672484 countsByYear W31996724842022 @default.
• W3199672484 countsByYear W31996724842023 @default.
• W3199672484 crossrefType "journal-article" @default.
• W3199672484 hasAuthorship W3199672484A5001738256 @default.
• W3199672484 hasAuthorship W3199672484A5002993236 @default.
• W3199672484 hasAuthorship W3199672484A5004940783 @default.
• W3199672484 hasAuthorship W3199672484A5016966644 @default.
• W3199672484 hasAuthorship W3199672484A5029600028 @default.
• W3199672484 hasAuthorship W3199672484A5044032137 @default.
• W3199672484 hasAuthorship W3199672484A5046440167 @default.
• W3199672484 hasAuthorship W3199672484A5059081660 @default.
• W3199672484 hasAuthorship W3199672484A5061765305 @default.
• W3199672484 hasAuthorship W3199672484A5063598635 @default.
• W3199672484 hasAuthorship W3199672484A5071706202 @default.
• W3199672484 hasAuthorship W3199672484A5075534279 @default.
• W3199672484 hasAuthorship W3199672484A5087468389 @default.
• W3199672484 hasConcept C121608353 @default.
• W3199672484 hasConcept C126322002 @default.
• W3199672484 hasConcept C126838900 @default.
• W3199672484 hasConcept C141071460 @default.
• W3199672484 hasConcept C143998085 @default.
• W3199672484 hasConcept C146357865 @default.
• W3199672484 hasConcept C151730666 @default.
• W3199672484 hasConcept C168563851 @default.
• W3199672484 hasConcept C203092338 @default.
• W3199672484 hasConcept C2777714996 @default.
• W3199672484 hasConcept C2779524853 @default.
• W3199672484 hasConcept C2780943399 @default.
• W3199672484 hasConcept C29730261 @default.
• W3199672484 hasConcept C509974204 @default.
• W3199672484 hasConcept C530470458 @default.
• W3199672484 hasConcept C71924100 @default.
• W3199672484 hasConcept C86803240 @default.
• W3199672484 hasConceptScore W3199672484C121608353 @default.
• W3199672484 hasConceptScore W3199672484C126322002 @default.
• W3199672484 hasConceptScore W3199672484C126838900 @default.
• W3199672484 hasConceptScore W3199672484C141071460 @default.
• W3199672484 hasConceptScore W3199672484C143998085 @default.
• W3199672484 hasConceptScore W3199672484C146357865 @default.
• W3199672484 hasConceptScore W3199672484C151730666 @default.
• W3199672484 hasConceptScore W3199672484C168563851 @default.
• W3199672484 hasConceptScore W3199672484C203092338 @default.
• W3199672484 hasConceptScore W3199672484C2777714996 @default.
• W3199672484 hasConceptScore W3199672484C2779524853 @default.
• W3199672484 hasConceptScore W3199672484C2780943399 @default.
• W3199672484 hasConceptScore W3199672484C29730261 @default.
• W3199672484 hasConceptScore W3199672484C509974204 @default.
• W3199672484 hasConceptScore W3199672484C530470458 @default.

• next